↓ Skip to main content

Development of Paramyosin as a Vaccine Candidate for Schistosomiasis

Overview of attention for article published in Frontiers in immunology, July 2015
Altmetric Badge

About this Attention Score

  • Average Attention Score compared to outputs of the same age
  • Above-average Attention Score compared to outputs of the same age and source (51st percentile)

Mentioned by

twitter
5 X users

Readers on

mendeley
46 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Development of Paramyosin as a Vaccine Candidate for Schistosomiasis
Published in
Frontiers in immunology, July 2015
DOI 10.3389/fimmu.2015.00347
Pubmed ID
Authors

Mario A. Jiz, Haiwei Wu, Remigio Olveda, Blanca Jarilla, Jonathan D. Kurtis

Abstract

Schistosomiasis, caused by three principal species of diecious trematodes (flatworms), currently afflicts over 250 million individuals, results in an estimated 2-15% chronic disability, and contributes to poor health and economic stagnation in endemic areas. Although schistosomiasis is effectively treated with praziquantel, rapid reinfection with rebound morbidity precludes effective control based on chemotherapy alone and justifies current efforts to develop vaccines for these parasites. Paramyosin (Pmy), an invertebrate muscle-associated protein, has emerged as a promising vaccine candidate for both Schistosoma mansoni and Schistosoma japonicum. Herein, we discuss the discovery of Pmy, its development as a vaccine candidate in rodents and bovines, as well as studies of naturally occurring immune responses to Pmy in prospective, observational human studies. We conclude with a proposed developmental plan to move Pmy toward Phase I clinical trials.

X Demographics

X Demographics

The data shown below were collected from the profiles of 5 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 46 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Australia 1 2%
Unknown 45 98%

Demographic breakdown

Readers by professional status Count As %
Student > Master 8 17%
Student > Ph. D. Student 7 15%
Researcher 6 13%
Student > Bachelor 4 9%
Student > Doctoral Student 3 7%
Other 11 24%
Unknown 7 15%
Readers by discipline Count As %
Agricultural and Biological Sciences 11 24%
Biochemistry, Genetics and Molecular Biology 7 15%
Immunology and Microbiology 6 13%
Medicine and Dentistry 4 9%
Mathematics 2 4%
Other 5 11%
Unknown 11 24%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 2. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 15 August 2015.
All research outputs
#15,740,207
of 25,374,647 outputs
Outputs from Frontiers in immunology
#15,377
of 31,520 outputs
Outputs of similar age
#140,475
of 275,683 outputs
Outputs of similar age from Frontiers in immunology
#74
of 155 outputs
Altmetric has tracked 25,374,647 research outputs across all sources so far. This one is in the 37th percentile – i.e., 37% of other outputs scored the same or lower than it.
So far Altmetric has tracked 31,520 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 8.4. This one is in the 47th percentile – i.e., 47% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 275,683 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 47th percentile – i.e., 47% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 155 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 51% of its contemporaries.